Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12374968 | 0.76 | PRKCA (0.30) | PRKCA | |
| SCHEMBL13316605 | 0.76 | OR51E2 (0.39) | TSHR | |
| SCHEMBL667279 | 0.76 | OR51E2 (0.39) | TSHR | |
| SCHEMBL26834901 | 0.75 | CA1 (0.30) | CA1CA2CA7CA14 | |
| SCHEMBL1705634 | 0.75 | SLC22A6 (0.36) | TSHRCA1CA2CA7CA14 | |
| SCHEMBL1703481 | 0.75 | RNPEP (0.34) | CA1CA2CA7CA14 | |
| SCHEMBL1705139 | 0.73 | ECE1 (0.34) | CA1CA2CA7CA14 | |
| SCHEMBL10034713 | 0.73 | ECE1 (0.34) | CA1CA2CA7CA14 | |
| SCHEMBL8041785 | 0.73 | RIPK1 (0.31) | — | |
| SCHEMBL8380546 | 0.72 | TSHR (0.31) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-9040531-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | PRKCA 3388/4885TSHR 3526/4885CA1 3499/4885 |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | PRKCA 3388/4885TSHR 3526/4885CA1 3499/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | PRKCA 3388/4885TSHR 3526/4885CA1 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.